



2012-2013

President

Bryan R. Haugen, M.D. (2012-2013)
Denver, Colorado

Secretary/Chief Operating Officer

John C. Morris, M.D. (2011-2015)
Rochester, Minnesota

Treasurer

David H. Sarne, M.D. (2007-2013)
Chicago, Illinois

President-Elect

Hossein Gharib, M.D. (2012-2013)
Rochester, Minnesota

Treasurer-Elect

Gregory W. Randolph, M.D. (2012-2013)
Boston, Massachusetts

Past-President

James A. Fagin, M.D. (2012-2013)
New York, New York

Directors

Peter A. Kopp, M.D. (2009-2013)
Chicago, Illinois

Elizabeth N. Pearce, M.D. (2009-2013)
Boston, Massachusetts

Victor J. Bernet, M.D. (2010-2014)
Jacksonville, Florida

Gerard M. Doherty, M.D. (2010-2014)
Boston, Massachusetts

Sissy M. Jhiang, Ph.D. (2010-2014)
Columbus, Ohio

Erik K. Alexander, M.D. (2011-2015)
Boston, Massachusetts

Martha A. Zeiger, M.D. (2011-2015)
Baltimore, Maryland

James V. Hennessey, M.D. (2012-2016)
Boston, Massachusetts

Susan A. Sherman, M.D. (2012-2016)
Aurora, Colorado

Executive Director

Barbara R. Smith, CAE

Headquarters' Office

American Thyroid Association
6066 Leesburg Pike, Suite 550
Falls Church, Virginia 22041

Phone: 703 998-8890

Fax: 703 998-8893

E-mail: bsmith@thyroid.org

Web: www.thyroid.org

Dear Colleagues,

I am pleased to welcome you to the ATA Spring Symposium and Research Summit on "Treatment of Hypothyroidism: Exploring the Possibilities."

On behalf of the American Thyroid Association (ATA) Board of Directors, we would like to express our appreciation for your presence here at the Westin Washington, DC City Center Hotel.

We will have many opportunities to share our understanding of how the latest basic and clinical research in thyroid hormone metabolism, transport, and action translates into recommendations for clinicians managing hypothyroid patients.

We will explore both the role of traditional thyroid hormone replacement therapy and alternatives to the use of levothyroxine alone. You are joining thought leaders and decision makers from the most prestigious medical institutions in North America and around the world, including top academic research scientists and clinical scientists and investigators.

On the research summit day, Thursday the 25th of April, experts in the field from North America and Europe will present and discuss recent studies on basic principles of thyroid hormone homeostasis and action.

The clinical symposium on Friday the 26th of April will re-examine the evidence concerning alternative therapies other than levothyroxine, to discuss gaps in our current knowledge of these therapies, and to determine whether new data provides reason to pursue these therapies. We will review the goals of levothyroxine therapy and examine the latest data regarding combination therapy, thyroid hormone analogs, and the potential for genetic variations to influence thyroid hormone therapy.

Please introduce yourself to me and let me know how we can improve the meeting experience and the ATA member experience. We also invite you to join the ATA if you are not already a member. We have much to offer and would enjoy your active participation in our work.

On behalf of the ATA members and the ATA Board of Directors, we welcome you.

Best regards,

Bryan R. Haugen, MD
President, American Thyroid Association